Editorial

On January 1, 2007, I appointed 25 eminent scientists
to 3-year terms on the

Journal of Pharmaceutical

Sciences (JPharmSci

TM

) Editorial Advisory Board

(EAB). The terms of these individuals will expire on
December 31, 2009. I am pleased to announce here
that the following individuals have accepted reap-
pointments to the

JPharmSci

TM

EAB for another 3-

year term (January 1, 2010–December 31, 2012):
Michael J. Akers, Baxter BioPharma Solutions;
Andreas

Bernkop-Schnu¨rch,

University

of

Innsbruck; Kathleen M.K. Boje, University at Buf-
falo; Daan J.A. Crommelin, Dutch Top Institute
Pharma; Claude Dagenais, Amgen; Hartmut Deren-
dorf, University of Florida; Stevin Gehrke, The
University of Kansas; Kai H. Griebenow, University
of Puerto Rico—Rı´o Piedras Campus; Anthony
Hickey, University of North Carolina; Patricia
Hurter, Vertex Pharmaceuticals, Inc.; LaToya Jones
Braun, University of Colorado Denver; Gerald B.
Kasting, University of Cincinnati; Kazuhiro Mor-
imoto, Hokkaido Pharmaceutical University; Annette
Mu¨llertz, University of Copenhagen; James E. Polli,
University of Maryland; Christopher J.H. Porter,
Monash University; Robert Price, University of Bath;
Hitoshi Sasaki, Nagasaki University Hospital; Pierre
Souillac, Eisai, Inc.; David R. Taft, Long Island
University; Ikumi Tamai, Kanazawa University;
Mike Tobyn, Bristol-Myers Squibb; Kishor Wasan,
University of British

Columbia; S.H. Yalkowsky,

University of Arizona; and Shinji Yamashita, Setsu-
nan University.

I would like to publicly thank the following

individuals who have served on the

JPharmSci

TM

.

EAB for the past 3 years: Ken-ichi Inui, Kyoto
University Hospital; Alexander Kabanov, University
of Nebraska Medical Center; Samir Mitragotri,
University of California, Santa Barbara; Catriona
O’Driscoll, University College Cork; Vinod Shah,
FIP; Kaneto Uekama, Sojo University; and Masaki
Otagiri, Kumamoto University.

I am also pleased to announce here the appoint-

ment of the following new EAB members to 3-year
terms starting on January 1, 2010: Hidetaka Akita,
Hokkaido University; Sven Deferme, PharmaXL;
Stefaan C. De Smedt, Ghent University; Robert K.
Evans,

Merck

Research

Laboratories;

Jennifer

S. Laurence, The University of Kansas; Amedeo
Marini, CSGI—University of Pavia; Miki Nakajima,
Kanazawa

University;

Yvonne

Perrie,

Aston

University;

Andreas

Schatzlein,

University

of

London; and Yoshimichi Sai, Kanazawa University
Hospital.

With these reappointments and new appointments

to the EAB, this advisory group remains at a steady-
state level of approximately 150 members. The
Associate Editors and I feel that the composition
of the EAB appropriately reflects the diversity of
scientific disciplines served by

JPharmSci

TM

and the

diversity of its international audience. In addition, we
feel that the EAB is sufficiently large to ensure that
an adequate number of experts are available to
conduct timely reviews of the approximately 800
manuscripts per year that are submitted to the
journal. Finally, I would like to take this opportunity
to thank the EAB members and the Associate Editors
for their dedication to

JPharmSci

TM

and for the time

and energy they have spent in the past 8.5 years
helping me as Editor to further strengthen this
journal and to better serve pharmaceutical scientists
worldwide.

Ronald T. Borchardt, Editor

Journal of Pharmaceutical Sciences

Received 23 October 2009; accepted 26 October 2009

Published online 30 November 2009 in Wiley InterScience

(www.interscience.wiley.com).

DOI 10.1002/jps.22023

Journal of Pharmaceutical Sciences, Vol. 99, 566 (2010)

ß

2009 Wiley-Liss, Inc. and the American Pharmacists Association

566

JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 2, FEBUARY 2010